id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12675 R47897 |
Mari (Carbamazepine), 2022 | Stillborn | throughout pregnancy | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 1.15 [0.04;30.40] C | 1/29 0/11 | 1 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8001 R24371 |
AlSheikh (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Stillbirth | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
16.71 [0.56;499.27] C excluded (control group) |
1/5 0/20 | 1 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8002 R24373 |
AlSheikh (Carbamazepine) (Controls unexposed, sick), 2020 | Stillbirth | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 6.43 [0.21;201.09] C | 1/5 0/8 | 1 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8082 R24683 |
Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Intrauterine fetal demise | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.44 [0.05;40.54] C excluded (control group) |
1/15 0/7 | 1 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8074 R24631 |
Aydin (Carbamazepine) (Controls unexposed, sick), 2020 | Intrauterine fetal demise | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 4.78 [0.18;125.99] C | 1/15 0/22 | 1 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6253 R16657 |
Arkilo (Carbamazepine), 2015 | Stillbirth | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 7.96 [0.35;178.85] C | 2/16 0/22 | 2 | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S333 R16614 |
Tomson (Carbamazepine), 2015 | Stillbirths | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.61 [1.00;6.82] C | 14/1,713 6/1,910 | 20 | 1,713 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6290 R16968 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Stillbirths | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.51 [0.20;1.32] C | 6/1,718 15/2,198 | 21 | 1,718 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6611 R18139 |
Holmes (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Stillborn | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Controls: mixed indications |
0.83 [0.07;9.14] C excluded (control group) |
1/573 2/948 | 3 | 573 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5877 R14645 |
Holmes (Carbamazepine) (Controls unexposed, disease free), 2011 | Stillborn | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 0.99 [0.04;24.52] C | 1/573 0/190 | 1 | 573 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5578 R14508 |
Diav-Citrin (Carbamazepine), 2001 | Stillbirths | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 1.95 [0.12;31.54] C | 1/108 1/210 | 2 | 108 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 8 studies | 1.53 [0.71;3.30] | 49 | 4,177 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick; 4: Carbamazepine; 5: Carbamazepine; 6: Carbamazepine) (Controls exposed to Lamotrigine, sick; 7: Carbamazepine) (Controls unexposed, disease free; 8: Carbamazepine;
Asymetry test p-value = 0.2996 (by Egger's regression)
slope=-0.2630 (0.6159); intercept=0.8106 (0.7140); t=1.1352; p=0.2996
excluded 6611, 8001, 8082